A Phase 2a Study to Evaluate the Dose-response, Safety, Tolerability, Efficacy, and Population Pharmacokinetics of Intravenous NTS-521 Infusions in the Early Recovery Treatment From Acute Ischemic Stroke

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 140 participants.

Also called NCT07742098

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 140 participants (planned count) (from the registry)
Sponsor
NeuroTrauma Sciences, LLC (from the registry)
Registry
  • NCT NCT07742098
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07742098. Randomized; quadruple masking; primary purpose treatment. Start 2026-10-31 (anticipated); primary completion 2028-12-15 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase 2a Study to Evaluate the Dose-response, Safety, Tolerability, Efficacy, and Population Pharmacokinetics of Intravenous NTS-521 Infusions in the Early Recovery Treatment From Acute Ischemic Stroke
Acronym
ACT-IVATE
Condition
Acute Ischemic Stroke
Intervention (Drug)
NTS-521
Intervention (Other)
Placebo Control
Lead sponsor
NeuroTrauma Sciences, LLC (class: industry)

Record details

Record id
cardio:ct-nct07742098
Content hash
2b3da222cd2eac0e507cea1f4181a2ede254968fbe4f531bcecb5d46ef9dcec3